Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer's Drug
• Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. • Roche and AbbVie have clini